Guideline 'Renal cell carcinoma';Richtlijn 'Niercelcarcinoom'

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 7, 2008, Pages 376-380

  Mulders, P F A ^a   Brouwers, A H ^b   Hulsbergen van Der Kaa, C A ^a   Van Lin, E N J Th ^a   Osanto, S ^c   De Mulder, P H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOTOXIC AGENT; INTERLEUKIN 2;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; METASTASECTOMY; MORBIDITY; NEPHRECTOMY; PARTIAL NEPHRECTOMY; PRACTICE GUIDELINE; PROGNOSIS; SHORT SURVEY; SURGICAL APPROACH; SURGICAL TECHNIQUE; TREATMENT INDICATION; TUMOR LOCALIZATION; WORLD HEALTH ORGANIZATION;

CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; NEPHRECTOMY; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 39549087194     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (20)

1. Signaleringscommissie Kanker van KWF Kankerbestrijding. Ranker in Nederland. Trends, prognoses en implicaties voor zorgvraag. Amsterdam: Nederlandse Kankerbestrijding/Koningin Wilhelmina Fonds; 2004.
2. Hricak H, Demas BE, Williams RD, McNamara MT, Hedgcock MW, Amparo EG, et al. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology. 1985;154: 709-15.
3. Amendola MA, King LR, Pollack HM, Gefter W, Kressel HY, Wein AJ. Staging of renal carcinoma using magnetic resonance imaging at 1.5 Tesla. Cancer. 1990;66:40-4.
4. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131-3.
5. Thoenes W, Störkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986;181:125-43.
6. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of tumours. Vol 7. Lyon: IARC Press; 2004.
7. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-24.
8. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6: 655-63.
9. Ficarra V, Righetti R, Martignoni G, D'Amico A, Pilloni S, Rubilotta E, et al. Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int. 2001;67:130-4.
10. Ficarra V, Righetti R, Pilloni S, D'Amico A, Maffei N, Novella G, et al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol. 2002;41:190-8.
11. Blom JHM, Poppel H van, Marechal JM, Jacqmin D, Sylvester R, Schröder FH, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol. 1999;36: 570-5.
12. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Poppel H van, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071-6.
13. Mickisch GH, Garin A, Poppel H van, Prijck L de, Sylvester R, Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Lancet. 2001;358:966-70.
14. Hemingway AP, Allison DJ. Complications of embolization: analysis of 410 procedures. Radiology. 1988;166:669-72.
15. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys. 1987;13:665-72.
16. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 1998; 338:1265-71.
17. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal cell carcinoma. Br J Urol. 1989;63:128-31.
18. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet. 1999;353:14-7.
19. Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H. Guidelines on renal cell cancer. European Association of Urology. Eur Urol. 2001;40:252-5.
20. Mulder PHM de, Haanen JBAG, Sleijfer S, Kruit WHJ, Gietema JA, Richel DJ, et al. Angiogeneseremmers voor de systemische behandeling van gemetastaseerd niercelcarcinoom: sunitinib, sorafenib, bevacizumab en temsirolimus. Ned Tijdschr Geneeskd. 2008;152: 371-5.